A double-blind randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children

Neurology

Volumn 52, Issue 7, 1999, Pages 1338-1344

  Elterman, Roy D ^a   Glauser, T A ^b   Wyllie, E ^e   Reife, R ^c   Wu, S C ^d   Pledger, G ^d  

^a Dallas Pediatric Neurology Associates   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c JOHNSON AND JOHNSON   (United States)

^d R W JOHNSON PHARMACEUTICAL RES I   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOPIRAMATE;

ADOLESCENT; AFFECTIVE NEUROSIS; AMNESIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; FATIGUE; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033594350     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.7.1338     Document Type: Article

References (16)

1. Ben-Menachem E, Henriksen O, Dam M, Schmidt D. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37: 539-543.
2. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46: 1684-1690.
3. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46: 1678-1683.
4. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-224.
5. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37: 763-768.
6. Bourgeois BFD. New antiepileptic drugs. Arch Neurol 1998; 55:1181-1183.
7. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epilepsies and epileptic syndromes. Epilepsia 1981;22:489-501.
8. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and encephalographic classification of epilepsies and epileptic syndromes. Epilepsia 1985;26:268-278.
9. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and encephalographic classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.
10. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 1982;35:124-133.
11. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, 1981.
12. Lehman EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden Day, 1975.
13. Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997;19:1294-1308.
14. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-780.
15. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;38:324-333.
16. Verity CM, Hosking G, Easter DJ, the Paediatric EPITEG Collaborative Group. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995;37:97-108.